Startups
Edit
Advanced Accelerator Applications
http://www.adacap.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 26.04.2024
Active
Our work is guided by our commitment to bring new innovations to patients and AAA is dedicated to developing treatments for several leading types of cancer through the application of precision, targeted radioligand therapy. Our ambition is to leverage industry leading pipeline to unlock the benefit of radioligand therapy across different tumor types. Our goal is to reimagine nuclear medicine.
Overview
Location
France, Auvergne-Rhône-Alpes, Saint-Genis-Pouilly
Employees
1001-5000
Total raised
$56.19M
Founded date
2002
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 31, 2022 | The global radioligand therapy market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% during the forecast period 2021-2031 | New York, March 31, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Radioligand Therapy Market - A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region - Analysis and Forecast... |
| Mar 23, 2022 | Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer | Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year sur... |
| Nov 26, 2020 | Radiopharmaceuticals: a new class of drugs for cancer patients, and a new road for Canada to lead global life sciences | The role of radiopharmaceuticals in health care may still be quite a mystery for many Canadians, but this area has a tremendous therapeutic and commercial potential in our country. Canada is already a global leader in radioisotope-based hea... |
| Oct 30, 2017 | Term Sheet — Monday, October 30 | I SCAM YOUS Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop “Thanks in part to the endorsements, in just a few weeks Centra’s founders raised over $30 million from investors around the wo... |
| Feb 17, 2014 | Advanced Accelerator Applications Raises €41M in Funding | Advanced Accelerator Applications, a Saint Genis Pouilly, France-based specialist in Molecular Nuclear Medicine (MNM), raised €41m in funding. The round was led by biotech and pharma investment company HBM Healthcare Investments Ltd (€20m),... |
| Jul 29, 2011 | Advanced Accelerator Applications Completes €40M Capital Increase | Advanced Accelerator Applications (AAA), a European developer of diagnostic and therapeutic applications and products, has completed a €40m capital increase. The fundraising was subscribed by existing and new shareholders, including private... |
Reviews 0
FAQ about Advanced Accelerator Applications
When was Advanced Accelerator Applications founded?
Advanced Accelerator Applications was founded in 2002.
How much funding has Advanced Accelerator Applications raised?
Advanced Accelerator Applications has raised $56.19M in total across 1 funding round.
What has the press written about Advanced Accelerator Applications?
Parsers VC has collected 7 articles mentioning Advanced Accelerator Applications, among them “The global radioligand therapy market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% d...” (Mar 31, 2022) and “Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate...” (Mar 23, 2022).
Is Advanced Accelerator Applications still active?
Yes, Advanced Accelerator Applications is active; its latest activity on Parsers VC dates from Apr 26, 2024.